One signature from Sheba does not cure leukemia, but it does move Racura Oncology from talking about EMILI to doing the hard, expensive work of enrolling patients. For a company at this stage, that distinction matters. Ethics approval for the seamless Phase 2b/3 RC220 study in relapsed or refractory acute myeloid leukemia is a real operational milestone, not the sort of chest-thumping headline investors should confuse with efficacy.
Sheba Gives the Program a Credible Starting Point
The Israeli site knows this drug family. Professor Arnon Nagler and the Sheba team previously studied RC110, an earlier formulation of (E,E)-bisantrene, in AML. That history appears to have eased the path: Israel's Ministry of Health said separate approval was unnecessary, although minor consent-form updates and institutional governance review still stand between this announcement and actual activation.
Racura expects Sheba to activate by the end of 2026 and dose its first EMILI patient in the first quarter of 2027. Those dates are targets, not appointments carved in stone. Clinical operations have a nasty habit of finding loose floorboards: contracts, site processes, patient screening, staffing, and cross-border regulatory work can all drag. Still, having a first approved center with direct bisantrene experience is plainly better than beginning from a cold start.
The Clinical Question Is Narrow and Important
EMILI is testing whether one seven-day cycle of RC220 can drive enough remission activity for adults with relapsed or refractory AML to proceed to an allogeneic stem-cell transplant. That is a serious, patient-relevant aim. For many patients in this setting, transplant is the main potentially curative route, but it generally requires bringing the disease under control first.
RC220 is Racura's peripheral-intravenous formulation of bisantrene. The company emphasizes that, unlike RC110, it can be infused through a peripheral vein rather than requiring a central line. Practical treatment delivery is not glamorous, yet it can matter in a very sick patient population. A nonclinical GLP bridging study reported on November 17, 2026 found equivalent drug exposure to RC110, but that is not a substitute for human outcome data.
- Phase 2b starts with six patients at 175 mg/m2.
- Up to 62 more patients may be randomized across dose pairs, bringing Phase 2b to as many as 68 patients.
- Interim looks after 11, 16, and 21 patients per arm can stop the dose-optimization stage early.
- The selected Phase 3 dose will weigh remission, transplant eligibility, safety, tolerability, pharmacokinetics, and biomarkers.
Old Signals Are Useful, Not a Free Pass
The prior Sheba studies provide a rationale, but the numbers are small enough to demand restraint. RC110 monotherapy produced four clinically meaningful responses among 10 heavily pretreated patients, including one complete remission. In a separate combination study, six of 15 evaluable patients responded meaningfully, with five complete remissions and six patients proceeding to transplant. Those results are encouraging in a brutal disease, yet they came from single-center, non-randomized work and involved an earlier formulation, including a combination regimen.
Small AML studies can point a program in the right direction; they cannot tell shareholders where the road ends.
The MYC angle adds scientific interest and plenty of uncertainty. Racura says MYC is overexpressed in roughly 90% of newly diagnosed AML cases and is notoriously difficult to target directly. Preclinical work suggests bisantrene can reduce MYC expression through G-quadruplex binding. The cited University of Newcastle collaboration includes cell and mouse data, though the 2026 bioRxiv report is a preprint rather than peer-reviewed research. EMILI's serial blood sampling may show whether MYC suppression occurs in patients, but a biomarker move and a clinical benefit are not automatically the same thing.
What RAC Holders Need to Watch Next
For RAC, the immediate financial message is modestly reassuring: management says Phase 2b is funded from existing cash. That removes one near-term overhang, not the bigger one. The company explicitly says Phase 3 would require additional funding, and advancement depends on Phase 2b data plus an End-of-Phase 2 regulatory meeting. Investors should not casually price seven years of possible U.S. orphan-drug exclusivity, or potential patent protection, as though approval were already nearby.
Phase 2b is expected to run 18 to 24 months, depending on recruitment, activated sites, and how many patients are needed to settle the dose. U.S., European, and Australian sites are planned for 2027 but remain subject to regulatory approvals and feasibility. The next tangible markers are a contract research organization, trial registration, FDA clearance, European authorization, site activation, and first dosing. This is progress, no doubt. It is also the opening bell for a long clinical proof exercise, where discipline beats excitement every time.